查看購物車
  • English
封面
市場調查報告書
商品編碼
1914704

臨床試驗外包市場－全球產業規模、佔有率、趨勢、機會及預測（依臨床試驗階段、治療領域、最終用戶、地區及競爭格局分類，2021-2031年）

Clinical Trial Outsourcing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Clinical Trial Phase, By Therapeutic Area, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球臨床試驗外包市場預計將從2025年的515.3億美元成長到2031年的771.2億美元，複合年成長率（CAGR）為6.95%。臨床試驗外包是指將研究任務（例如通訊協定設計、資料管理和現場監查）外包給外部供應商，以降低固定成本並提高營運柔軟性。該市場的主要驅動力是製藥研發公司，這些公司需要複雜治療方法的專業知識，並負責管理全球整合研究的物流。根據臨床研究組織協會（ACRO）統計，2024年，其成員公司參與或進行了8854項研究，涉及全球約170萬名患者。

市場概覽
預測期 2027-2031
市場規模：2025年 515.3億美元
市場規模：2031年 771.2億美元
複合年成長率：2026-2031年 6.95%
成長最快的細分市場 腫瘤學
最大的市場 北美洲

儘管市場持續擴張，但維持不同地區品管的一致性仍是限制市場成長的一大障礙。隨著申辦方將試驗擴展到多個國家以確保患者群體的多樣性，遵守不同的法規結構和嚴格的數據完整性標準的需求帶來了顯著的營運複雜性，並可能延長核准時間。

市場促進因素

與藥物研發相關的成本不斷攀升，正促使企業轉向外包，以此作為降低財務風險和維持研發管線永續性的策略性舉措。隨著藥物發現過程變得越來越依賴資本投入，申辦方正將臨床營運外包給外部供應商，有效地將固定基礎設施成本轉化為可控的可變支出。根據美國藥品研究與製造商協會（PhRMA）於2024年8月發布的《2024年度會員調查報告》，預計會員公司在2023年將在研發領域投入總計1035億美元，這凸顯了巨大的財務負擔，也促使企業轉向受託研究機構（CRO）。這種模式使研發人員能夠在應對現代藥物研發高風險環境的同時，最佳化資源配置。

同時，中小型生物技術公司臨床試驗活動的激增正在顯著改變外包格局。這些小規模的公司往往缺乏內部基礎設施，嚴重依賴服務供應商來處理複雜的營運和監管合規事宜。根據摩根大通於2024年1月發布的《2024年生物製藥許可創投年度報告》，2023年生物製藥創投將達到231億美元，這將為不斷成長的研發管線提供支持，而這些研發管線需要外部支持。大量資金的湧入直接推動了對能夠管理全球研發的專業供應商的需求，Icon Plc 2023年全年營收達81.2億美元便印證了這一點。

市場挑戰

確保跨區域的品管一致性和嚴格的監管合規性是全球臨床試驗外包市場的一大瓶頸。申辦方正將試驗範圍擴展至全球，以涵蓋不同的患者群體，但各地研究中心能力的差異造成了營運環境的碎片化。這種分散化迫使外包供應商投入大量資金用於糾正措施和額外監控，以維護資料完整性，從而直接降低了外包模式實施的速度和成本效益。區域差異導致供應商無法確保統一的合規性，延長了核准時間，並限制了市場擴充性。

這種營運上的不穩定性因研究中心層級的資源限制而進一步加劇，阻礙了複雜通訊協定的執行。根據臨床研究中心協會 (SCRS) 發布的《2024 年研究中心環境調查報告》，超過 60% 的研究中心專業人員面臨嚴重的員工短缺問題。合格人員的匱乏直接阻礙了滿足各種法規結構所需的嚴格監測和資料管理。因此，由於資源匱乏地區監管合規的物流需求超過了全球部署帶來的益處，市場難以維持成長勢頭。

市場趨勢

機器學習 (ML) 和人工智慧 (AI) 的融合正在從根本上改變臨床試驗的進行方式，顯著提升營運效率和預測分析能力。這一趨勢已從理論概念發展到風險評估和患者識別等實際應用，使申辦方能夠分析大量資料集，從而精準最佳化通訊協定。借助這些演算法，外包供應商可以預測試驗中心可能出現的問題，並顯著縮短研發週期，以應對日益複雜的全球性研究。正如 2025 年 6 月《應用臨床試驗》雜誌發表的題為“人工智慧解決方案影響的新見解”的報導中所述，塔夫茨藥物研發研究中心 (CSDD) 的一項調查發現，35.2% 的申辦方和契約研究組織 (CRO) 已在臨床試驗開展過程中部分或全部應用了人工智慧/機器學習技術。

同時，混合型和分散式臨床試驗 (DCT) 模式的普及正在改變市場結構，減少對實體試驗點的依賴。這種模式透過直接面向患者的物流和遠端監測，滿足了多樣化患者招募和留存的關鍵需求。隨著業界擴展這些混合工作流程，申辦方正從試驗計畫轉向企業級數位化策略，這就要求供應商提供整合平台，以確保在傳統環境之外無縫收集數據。 Medable 在 2025 年 1 月發布的新聞稿《Medable 透過產品組合級電子臨床結果評估 (eCOA) 部署實現 80% 的收入成長》中反映了這種日益成長的數位化依賴性，該新聞稿記錄了 2024 年收入成長 80%，原因是申辦方轉向可擴展的產品組合級數位化試驗投資。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球臨床試驗外包市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 臨床試驗階段（0期、1期、2期、3期、4期）
    • 依治療領域（腫瘤學、血液學、中樞神經系統、心血管及代謝、呼吸系統、傳染病、感染疾病學、罕見疾病、醫療設備、其他）
    • 依最終用戶分類（生物技術/製藥公司、醫療設備公司、學術/研究機構）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美臨床試驗外包市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲臨床試驗外包市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區臨床試驗外包市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲臨床試驗外包市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲臨床試驗外包市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球臨床試驗外包市場：SWOT分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • ICON plc
  • PAREXEL International Corp.
  • Thermo Fisher Scientific, Inc
  • Sygnature Discovery Limited
  • WuXi AppTec Co., Ltd.
  • Laboratory Corporation of America Holdings
  • Jubilant Biosys Limited
  • Charles River Laboratories International, Inc
  • Albany Molecular Research, Inc
  • Syneos Health Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 12840

The Global Clinical Trial Outsourcing Market is projected to expand from USD 51.53 Billion in 2025 to USD 77.12 Billion by 2031, registering a compound annual growth rate (CAGR) of 6.95%. Clinical trial outsourcing entails delegating research tasks, including protocol design, data management, and site monitoring, to external vendors to lower fixed costs and improve operational flexibility. This market is primarily fueled by pharmaceutical developers needing specialized expertise for complex therapies while managing the logistics of globalized studies. According to the Association of Clinical Research Organizations (ACRO), member companies participated in or conducted 8,854 studies involving roughly 1.7 million patients globally in 2024.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 51.53 Billion
Market Size 2031USD 77.12 Billion
CAGR 2026-20316.95%
Fastest Growing SegmentOncology
Largest MarketNorth America

Despite this ongoing expansion, upholding consistent quality control across various geographic regions stands as a major obstacle to market growth. As sponsors increasingly spread trials across multiple countries to secure diverse patient enrollment, the necessity of strictly adhering to distinct regulatory frameworks and data integrity standards introduces significant operational complexity that can prolong approval timelines.

Market Driver

Rising costs associated with pharmaceutical R&D and drug development are compelling a strategic shift toward outsourcing to limit financial risks and sustain pipeline viability. As the drug discovery process becomes more capital-intensive, sponsors are delegating clinical operations to external vendors, effectively converting fixed infrastructure costs into manageable variable expenses. According to the '2024 PhRMA Annual Membership Survey' released by PhRMA in August 2024, member companies collectively invested $103.5 billion in R&D during 2023, a figure that highlights the substantial financial burden driving the transition to contract research organizations. This model enables developers to optimize resource allocation while navigating the high-stakes landscape of modern therapeutic development.

Concurrently, the increase in clinical trial activities by small and mid-sized biotech firms is significantly reshaping the outsourcing environment. These smaller entities, often lacking internal infrastructure, depend heavily on full-service providers to handle complex operational and regulatory tasks. J.P. Morgan's '2024 Annual Biopharma Licensing and Venture Report' from January 2024 indicates that biopharma venture investment hit $23.1 billion in 2023, supporting a strong pipeline of studies requiring external assistance. This capital influx directly drives demand for specialized vendors capable of managing global studies, as evidenced by Icon Plc recording full-year 2023 revenue of $8.12 billion in 2024.

Market Challenge

The difficulty of ensuring consistent quality control and strict regulatory adherence across diverse geographic regions serves as a critical bottleneck for the Global Clinical Trial Outsourcing Market. Although sponsors broaden trials globally to access diverse patient pools, variations in local site capabilities lead to a fragmented operational landscape. This fragmentation compels outsourcing vendors to invest heavily in remediation and additional oversight to maintain data integrity, which directly diminishes the speed and cost-efficiency that drive the outsourcing model. When vendors cannot ensure uniform compliance due to regional disparities, approval timelines extend, and market scalability is restricted.

This operational instability is further aggravated by resource constraints at the site level, which hinder the execution of complex protocols. The Society for Clinical Research Sites (SCRS) reported in its 2024 Site Landscape Survey that over 60% of site professionals face significant staffing shortages. This scarcity of qualified personnel directly impedes the rigorous monitoring and data management necessary to navigate varying regulatory frameworks. Consequently, the market struggles to maintain growth momentum as the logistical demands of ensuring regulatory compliance in under-resourced regions outweigh the advantages of global reach.

Market Trends

The integration of Machine Learning (ML) and Artificial Intelligence (AI) is fundamentally transforming clinical trial execution by improving operational efficiency and predictive analytics. This trend has advanced from theoretical concepts to practical application in risk assessment and patient identification, enabling sponsors to analyze massive datasets for accurate protocol optimization. By utilizing these algorithms, outsourcing vendors can forecast site performance issues and significantly shorten development timelines to address the rising complexity of global studies. As noted in the article 'New Insights On the Impact of AI-Enabled Solutions' by Applied Clinical Trials in June 2025, a survey by the Tufts Center for the Study of Drug Development (CSDD) revealed that 35.2% of sponsor companies and CROs have partially or fully adopted AI/ML activities related to clinical trial execution.

Simultaneously, the widespread acceptance of Hybrid and Decentralized Clinical Trial (DCT) models is reshaping the market by reducing reliance on physical sites. This model meets critical needs for diverse enrollment and patient retention through direct-to-patient logistics and remote monitoring. As the industry scales these hybrid workflows, sponsors are shifting from pilot programs to enterprise-wide digital strategies, requiring vendors to offer integrated platforms that ensure seamless data capture outside traditional settings. This increase in digital reliance is reflected in Medable's January 2025 press release, 'Medable Reports 80% Revenue Growth from Portfolio-Level eCOA Adoption', which recorded an 80% revenue increase for 2024 driven by sponsors moving toward scalable, portfolio-level digital trial investments.

Key Market Players

  • ICON plc
  • PAREXEL International Corp.
  • Thermo Fisher Scientific, Inc
  • Sygnature Discovery Limited
  • WuXi AppTec Co., Ltd.
  • Laboratory Corporation of America Holdings
  • Jubilant Biosys Limited
  • Charles River Laboratories International, Inc
  • Albany Molecular Research, Inc
  • Syneos Health Inc

Report Scope

In this report, the Global Clinical Trial Outsourcing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clinical Trial Outsourcing Market, By Clinical Trial Phase

  • Phase 0
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

Clinical Trial Outsourcing Market, By Therapeutic Area

  • Oncology
  • Hematology
  • Central Nervous System
  • Cardiovascular/Metabolic
  • Respiratory
  • Infectious Diseases
  • Immunology
  • Rare Diseases
  • Medical Devices
  • Others

Clinical Trial Outsourcing Market, By End User

  • Biotechnology & Pharmaceutical Companies
  • Medical Device Companies
  • Academic & Research Institutions

Clinical Trial Outsourcing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clinical Trial Outsourcing Market.

Available Customizations:

Global Clinical Trial Outsourcing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Clinical Trial Outsourcing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Clinical Trial Phase (Phase 0, Phase 1, Phase 2, Phase 3, Phase 4)
    • 5.2.2. By Therapeutic Area (Oncology, Hematology, Central Nervous System, Cardiovascular/Metabolic, Respiratory, Infectious Diseases, Immunology, Rare Diseases, Medical Devices, Others)
    • 5.2.3. By End User (Biotechnology & Pharmaceutical Companies, Medical Device Companies, Academic & Research Institutions)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Clinical Trial Outsourcing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Clinical Trial Phase
    • 6.2.2. By Therapeutic Area
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Clinical Trial Outsourcing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Clinical Trial Phase
        • 6.3.1.2.2. By Therapeutic Area
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Clinical Trial Outsourcing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Clinical Trial Phase
        • 6.3.2.2.2. By Therapeutic Area
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Clinical Trial Outsourcing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Clinical Trial Phase
        • 6.3.3.2.2. By Therapeutic Area
        • 6.3.3.2.3. By End User

7. Europe Clinical Trial Outsourcing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Clinical Trial Phase
    • 7.2.2. By Therapeutic Area
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Clinical Trial Outsourcing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Clinical Trial Phase
        • 7.3.1.2.2. By Therapeutic Area
        • 7.3.1.2.3. By End User
    • 7.3.2. France Clinical Trial Outsourcing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Clinical Trial Phase
        • 7.3.2.2.2. By Therapeutic Area
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Clinical Trial Outsourcing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Clinical Trial Phase
        • 7.3.3.2.2. By Therapeutic Area
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Clinical Trial Outsourcing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Clinical Trial Phase
        • 7.3.4.2.2. By Therapeutic Area
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Clinical Trial Outsourcing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Clinical Trial Phase
        • 7.3.5.2.2. By Therapeutic Area
        • 7.3.5.2.3. By End User

8. Asia Pacific Clinical Trial Outsourcing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Clinical Trial Phase
    • 8.2.2. By Therapeutic Area
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Clinical Trial Outsourcing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Clinical Trial Phase
        • 8.3.1.2.2. By Therapeutic Area
        • 8.3.1.2.3. By End User
    • 8.3.2. India Clinical Trial Outsourcing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Clinical Trial Phase
        • 8.3.2.2.2. By Therapeutic Area
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Clinical Trial Outsourcing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Clinical Trial Phase
        • 8.3.3.2.2. By Therapeutic Area
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Clinical Trial Outsourcing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Clinical Trial Phase
        • 8.3.4.2.2. By Therapeutic Area
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Clinical Trial Outsourcing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Clinical Trial Phase
        • 8.3.5.2.2. By Therapeutic Area
        • 8.3.5.2.3. By End User

9. Middle East & Africa Clinical Trial Outsourcing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Clinical Trial Phase
    • 9.2.2. By Therapeutic Area
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Clinical Trial Outsourcing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Clinical Trial Phase
        • 9.3.1.2.2. By Therapeutic Area
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Clinical Trial Outsourcing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Clinical Trial Phase
        • 9.3.2.2.2. By Therapeutic Area
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Clinical Trial Outsourcing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Clinical Trial Phase
        • 9.3.3.2.2. By Therapeutic Area
        • 9.3.3.2.3. By End User

10. South America Clinical Trial Outsourcing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Clinical Trial Phase
    • 10.2.2. By Therapeutic Area
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Clinical Trial Outsourcing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Clinical Trial Phase
        • 10.3.1.2.2. By Therapeutic Area
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Clinical Trial Outsourcing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Clinical Trial Phase
        • 10.3.2.2.2. By Therapeutic Area
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Clinical Trial Outsourcing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Clinical Trial Phase
        • 10.3.3.2.2. By Therapeutic Area
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Clinical Trial Outsourcing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. ICON plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. PAREXEL International Corp.
  • 15.3. Thermo Fisher Scientific, Inc
  • 15.4. Sygnature Discovery Limited
  • 15.5. WuXi AppTec Co., Ltd.
  • 15.6. Laboratory Corporation of America Holdings
  • 15.7. Jubilant Biosys Limited
  • 15.8. Charles River Laboratories International, Inc
  • 15.9. Albany Molecular Research, Inc
  • 15.10. Syneos Health Inc

16. Strategic Recommendations

17. About Us & Disclaimer